INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, ...

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of ...

. Introduction: By depleting autoreactive B cells, CD19-targeted CAR-T have shown early yet promising efficacy in treating patients with B cell-driven autoimmune diseases. However, the clinical ...

The panels used were (1) Immune Cell Composition (markers: CD45 VioBlue, CD4 VioGreen, CD3 FITC, CD56 PE, CD16 PE, 7AAD, CD19 PE-Vio770, CD14 APC, and CD8 APC-Vio770 from Miltenyi Biotec, Bergisch ...

MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB” or the "Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release ...

Marketed as Tecartus (autologous anti-CD19-transduced CD3+) in Europe, the drug was approved in the EU in December for adults with relapsed or refractory mantle cell lymphoma after two or more ...

This subcutaneous CD19/CD3-directed bispecific-TCE (BiTE) demonstrated deep B-cell depletion and a favourable safety profile with weekly injections in Phase 1 trials for non-Hodgkin’s lymphoma ...

Clinical data on a CD19-directed CAR-T cell therapy in lupus ... against B cells but Cue has identified their reliance on CD3 as a potential weakness. As CEO Daniel Passeri explained at a Piper ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...